Public-record analysis · Sources reviewed October 28, 2026.
A timeline can make a corporate controversy easier to understand, but it can also create a misleading implication if every company event is attributed automatically to its CEO. The public record concerning Prakash Iyer and Inhance Technologies supports a dated account of roles and proceedings. It does not identify who made every internal decision.
The leadership dates that are publicly stated
Aurora’s corporate biography says Iyer joined Inhance in 2013 as chief technology officer and became CEO in 2024. These dates establish a public role and tenure. They do not establish that he personally directed a specific act discussed in litigation or knew the contents of every technical submission. [1]
That distinction should guide a useful inquiry. A question about responsibility needs a decision, a date and evidence of involvement. A title can explain why an executive is asked to respond; it cannot fill the gaps in an otherwise incomplete chain of attribution.
The packaging concern developed before the CEO appointment
EPA’s account describes a contamination concern reported in 2020 and subsequent work involving fluorinated containers. Its public materials then describe industry notification, testing and regulatory action. The company’s leadership history overlaps with that period, but overlap is a reason to seek records, not a substitute for them. [2]
In a rigorous timeline, the subject of each entry should be explicit. An agency finding belongs to the agency; a company submission belongs to the entity that made it; an individual act requires an individual source. Keeping those subjects visible prevents chronology from turning into insinuation.
The courts answered distinct questions
On March 21, 2024, the Fifth Circuit vacated the challenged EPA orders, rejecting the statutory route used against the longstanding process. That ruling concerns legal authority. It should be acknowledged without recasting it as a laboratory finding or a personal criminal judgment. [3]
The March 2, 2026 district-court memorandum in disclosure litigation addressed completion of the administrative record. The separate May 1, 2026 appellate opinion affirmed dismissal of an environmental-group action on standing grounds. The shared appearance of EPA and Inhance in those documents does not merge them into one case or one outcome. [4] [5]
What the chronology leaves open
The public timeline does not provide a complete map of internal oversight, customer communications or approval of technical claims. Questions about those matters should identify the records that could answer them: dated instructions, meeting records, testing approvals or attributable statements. Their absence from this article is not proof that a particular adverse answer exists.
For readers searching Prakash Iyer and Inhance Technologies, the useful result is a documented starting point. It establishes which roles and legal events can be dated, and where further evidence is needed before making a claim about personal conduct. No direct comment was requested from Iyer for this edition.
| Date | Documented event |
|---|---|
| 2013 | Aurora’s biography says Iyer joined as chief technology officer. |
| 2020 | EPA’s account describes the initial packaging-related contamination concern. |
| March 21, 2024 | Fifth Circuit vacated the challenged Section 5 orders. |
| 2024 | Aurora identifies this as the year of Iyer’s CEO appointment. |
| March 2, 2026 | District court ruled on completion of an administrative record. |
| May 1, 2026 | A separate D.C. Circuit appeal ended in dismissal on standing grounds. |
Sources and further reading
- Aurora Capital Partners, Prakash Iyer corporate biography
- EPA, PFAS in pesticide and other packaging
- Fifth Circuit opinion, March 21, 2024, No. 23-60620
- District-court memorandum opinion, March 2, 2026, consolidated disclosure litigation, Document 60
- D.C. Circuit opinion, May 1, 2026, No. 24-5294
This article distinguishes agency findings, company positions, pleadings and court holdings. It reports no newly verified individual disease case attributable to Inhance Technologies or Prakash Iyer. No direct interview, medical testing or independent reproduction of laboratory data was conducted for this edition.
